- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07754916
Comparison of Liposomal Bupivacaine Paravertebral Nerve Block Versus Intercostal Nerve Block on Postoperative Glycemic Variability in Patients Undergoing Minimally Invasive Pulmonary Resection: A Randomized Controlled Non-Inferiority Trial
9 augusti 2026 uppdaterad av: Xiangya Hospital of Central South University
In this randomized controlled non-inferiority trial, we will test whether liposomal bupivacaine intercostal nerve block is non-inferior to paravertebral nerve block for the coefficient of variation (CV) of glucose during the 0- to 48-hour postoperative period, using a non-inferiority margin of Δ = 0.025 for the absolute CV difference.
We will also compare the two blocks regarding their effects on postoperative glucose, autonomic function, stress, insulin resistance, acute pain, recovery quality, procedure duration, complications, and hemodynamic stability.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
64
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Yingqi Weng, MD
- Telefonnummer: +86-15074834690
- E-post: 651922615@qq.com
Studera Kontakt Backup
- Namn: Hongying Zhu
- Telefonnummer: +86-15970330540
- E-post: 2506627021@qq.com
Studieorter
-
-
Hunan
-
Changsha, Hunan, Kina, 410000
- Department of Anesthesiology, Xiangya Hospital, Central South University
-
Kontakt:
- Yingqi Weng, MD
- Telefonnummer: +86-15074834690
- E-post: 651922615@qq.com
-
Kontakt:
- Hongying Zhu
- Telefonnummer: +86-15970330540
- E-post: 2506627021@qq.com
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Aged 18-70 years, with American Society of Anesthesiologists (ASA) physical status I-III, scheduled for uniportal or multiportal video-assisted thoracoscopic (VATS) minimally invasive pulmonary resection under general anesthesia.
- Planned to receive liposomal bupivacaine regional block analgesia under direct thoracoscopic visualization.
- Body mass index (BMI) 18-30 kg/m².
- Willing and able to cooperate with the study procedures and provide written informed consent.
Exclusion Criteria:
- Regularly taking beta-blockers (for ≥2 weeks) or long-term use of high-dose glucocorticoids (prednisone ≥20 mg/day for >2 weeks).
- Known history of diabetes mellitus, or regular use of glucose-lowering agents (oral agents or insulin) before surgery.
- Planned postoperative admission to the intensive care unit (ICU).
- Concurrent severe cardiac (New York Heart Association class III or higher), hepatic (e.g., cirrhosis), or renal insufficiency (glomerular filtration rate <30 mL/min/1.73 m²), or neuropsychiatric disorders.
- Contraindications to regional block or to any study medication, including but not limited to infection or tumor invasion at the puncture site, coagulation disorders, or allergy to any drug used in the study.
- Alcohol dependence: meeting the DSM-5 criteria for severe alcohol use disorder (AUD), or clinically judged as alcohol dependence (regardless of liver function status).
- Pregnancy or lactation (for men and women of childbearing potential, effective contraception is required until 3 months after surgery, and donation of sperm or eggs is prohibited).
- Participation in another interventional drug trial.
- Regular use of analgesics for acute or chronic pain within 2 weeks before surgery.
- Concurrent severe infection.
- Prior ipsilateral intrathoracic surgery or severe pleural adhesions (estimated to preclude successful thoracoscopic visualization and completion of the block).
- Psychiatric or cognitive disorders that would impair the ability to cooperate with postoperative follow-up.
- Any other condition that, in the investigator's judgment, would make the patient unsuitable for participation in the trial (for medical or safety reasons).
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: kontrollgrupp
|
Following induction of general anesthesia, the surgeon will perform thoracoscopic intercostal nerve blocks using liposomal bupivacaine (prepared as 20 mL of 6.65 mg/mL solution diluted with 20 mL normal saline to 40 mL total) to cover the surgical incision and pleural irritation areas, typically at the 3rd-8th intercostal spaces.
Under direct vision, 4.0 mL of the diluted solution will be injected at each space at a site 3-5 cm lateral to the spine, for a total liposomal bupivacaine dose of 159.6 mg (24 mL).
Injections will be slow and fractionated, with aspiration for blood or CSF before each injection, and care will be taken to prevent overdose and systemic toxicity.
|
|
Experimentell: behandlingsgrupp
|
Following induction of general anesthesia, a T3-T8 paravertebral nerve block will be performed by the surgeon under thoracoscopic guidance.
Liposomal bupivacaine (6.65 mg/mL) will be diluted with normal saline (20 mL + 20 mL = 40 mL total).
Under direct vision, 4.0 mL of the diluted solution will be injected evenly at each level, lateral to the sympathetic chain, for a total liposomal bupivacaine dose of 159.6 mg (24 mL).
Injections will be slow and fractionated, with aspiration for blood or cerebrospinal fluid prior to each injection, and care will be taken to prevent overdose and systemic toxicity.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Coefficient of Variation of Blood Glucose
Tidsram: 48 hours post-surgery
|
48 hours post-surgery
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Glycated Serum Protein (GSP)
Tidsram: Preoperatively and on the first postoperative day
|
Preoperatively and on the first postoperative day
|
|
|
Heart Rate Variability
Tidsram: Preoperatively and on the first postoperative day, the second postoperative day, and the third postoperative day
|
Preoperatively and on the first postoperative day, the second postoperative day, and the third postoperative day
|
|
|
Fasting Serum Insulin
Tidsram: Preoperatively and on the first postoperative day
|
Preoperatively and on the first postoperative day
|
|
|
Numerical Rating Scale (NRS) Pain Score
Tidsram: Preoperatively and on the first postoperative day, the second postoperative day, and the third postoperative day
|
Numerical Rating Scale (NRS) Pain Score Scale range: 0 (no pain) to 10 (worst imaginable pain).
Higher scores indicate more severe pain.
|
Preoperatively and on the first postoperative day, the second postoperative day, and the third postoperative day
|
|
Fasting C peptide
Tidsram: Preoperatively and on the first postoperative day
|
Serum fasting C-peptide concentration measured by chemiluminescent immunoassay
|
Preoperatively and on the first postoperative day
|
|
Cortisol
Tidsram: Preoperatively and on the first postoperative day
|
Serum cortisol concentration measured by chemiluminescent immunoassay
|
Preoperatively and on the first postoperative day
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Utredare
- Huvudutredare: Yingqi Weng, MD, Department of Anesthesiology, Xiangya Hospital, Central South University
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 augusti 2026
Primärt slutförande (Beräknad)
1 februari 2027
Avslutad studie (Beräknad)
28 februari 2027
Studieregistreringsdatum
Först inskickad
28 juli 2026
Först inskickad som uppfyllde QC-kriterierna
4 augusti 2026
Första postat (Faktisk)
10 augusti 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
12 augusti 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
9 augusti 2026
Senast verifierad
1 juli 2026
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- Ethics Approval No. 202606086
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
IPD-planbeskrivning
Individual participant data will not be shared externally.
All raw data are restricted to the research team to protect participants' privacy.
Data sharing plans have not been established at this stage.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .